Home > Insider Trading > Filing (0001209191-17-056639)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1293971	Bluebird Bio Inc.	BLUE	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1578251	T. Jeffrey Walsh	C/O Bluebird Bio, Inc. 60 Binney Street Cambridge MA 02142	Chief Financial	No	Yes	No	Yes

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-10-10	4,900	$5.50	32,205	No	4	M	Direct
Common Stock	Disposition	2017-10-10	2,800	$129.43	29,405	No	4	S	Direct
Common Stock	Disposition	2017-10-10	1,600	$130.27	27,805	No	4	S	Direct
Common Stock	Disposition	2017-10-10	500	$131.80	27,305	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2017-10-10	4,900	$0.00	4,900	$5.50

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
62,585		2023-01-16	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016.
The range of prices for the transaction reported on this line was $129.00 to $129.95. The average weighted price was $129.4283. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The range of prices for the transaction reported on this line was $130.00 to $130.55. The average weighted price was $130.2655. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
This option to purchase shares of our common stock granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.